在患有喘的患者中,贝塔抑制剂的实际处方
1College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae, Republic of Korea.
Pharmacoepidemiology and drug safety
|August 1, 2024
概括
贝塔抑制剂经常被处方给喘患者,卡维迪洛尔和普拉诺洛尔是常见的. 由于潜在的喘恶化和与喘药物的药物相互作用,建议谨慎使用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
- 临床药房 临床药房
背景情况:
- β-阻断剂 (β-阻断剂) 广泛用于心血管疾病.
- 喘患者可能需要β抑制剂,但这些药物可以加剧呼吸道症状.
- 了解喘中β-阻断剂的处方模式对于患者的安全至关重要.
研究的目的:
- 为了研究被诊断患有喘的患者的β-阻断剂 (β-阻断剂) 处方的模式.
- 为了确定特定的β-阻断剂及其在喘患者处方时的频率.
主要方法:
- 使用韩国国家患者样本 (NPS) 数据进行的回顾性横截面研究.
- 使用健康保险审查和评估服务 (HIRA) 的通用代码识别了β-阻断剂和喘药物处方.
- 通过共同处方或重叠的处方日期来定义同时使用.
主要成果:
- 卡维迪洛尔和普拉诺洛尔是喘患者最常被处方的非选择性β抑制剂 (非SB).
- 比索普罗洛尔,阿提诺洛尔和内比沃洛尔是最常被处方的选择性β阻断剂 (SB).
- 接受β阻断剂治疗的喘患者中,很大一部分人也有一些喘药物的重叠处方,特别是β2-激动剂和支气管扩展剂.
结论:
- 非选择性β-阻断剂,如卡维迪洛尔和普拉诺洛尔,通常被处方给喘患者.
- 同时使用β-阻断剂和喘药物,特别是支气管扩展剂是常见的.
- 对喘患者开设β-阻断剂需要仔细考虑,以减轻喘恶化和不良药物相互作用的风险.
相关概念视频
01:28Antihypertensive Drugs: Types of β-Blockers
620
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
620
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
244
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
244
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
582
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
582
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:22Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K